Corrigendum: Targeting tumor gene by shRNA-expressing Salmonella-mediated RNAi (Gene Therapy (2010) DOI: 10.1038/gt.2010.112);Targeting tumor gene by shRNA-expressing Salmonella-mediated RNAi

Gene Therapy

Volumn 18, Issue 1, 2011, Pages 95-105

  Guo, H ^a   Zhang, J ^a   Inal, C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

attenuated S. enterica serovar typhimurium 7207; bacterial delivery; pSLS plasmid; RNAi; shRNA

Indexed keywords

APC PROTEIN; CYCLIN D1; MYC PROTEIN; SHORT HAIRPIN RNA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM CULTURE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CTNNB1 GENE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; MUCOSA; NONHUMAN; PLASMID; POLYP; PRIORITY JOURNAL; RNA INTERFERENCE; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SEROTYPE; SMALL INTESTINE; TUMOR GENE; TUMOR XENOGRAFT;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS; MUS; SALMONELLA; SALMONELLA ENTERICA; SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR TYPHIMURIUM;

EID: 78650975554     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.154     Document Type: Erratum

References (25)

1. Timmons L, Fire A. Specific interference by ingested dsRNA. Nature 1998; 395: 854.
2. Broeke A, Burny A. Retroviral vector biosafety: lessons from sheep. J Biomed Biotechnol 2002; 2003: 9-12.
3. Guarino A, Lo Vecchio A, Canani RB. Probiotics as prevention and treatment for diarrhea. Curr Opin Gastroenterol 2009; 25: 18-23. Review.
4. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009; 104: 1033-1049.
5. Fedorak RN. Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol 2008; 42 (Suppl 3 Pt 1): S111-S115.
6. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother 2002; 25: 218-225.
7. Theys L, Barbe S, Landuyt W, Nuyt S, Van Mellaert L, Wouter B, et al. Tumor-Specific gene delivery using genetically engineered bacteria. Current Gene Ther 2003; 3: 207-221.
8. Zhao M, Yang M, Li XM, Jiang P, Baranov E, Li SK, et al. Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. PNAS 2005; 102: 755-760.
9. Low KB, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, et al. Lipid A mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999; 17: 37-41.
10. Yang N, Zhu X, Chen L, Li S, Ren D. Oral administration of attenuated S. typhimurium carrying shRNA-expressing vectors as a cancer therapeutic. Cancer Biol Ther 2008; 7: 145-151.
11. Xu DQ, Zhang L, Kopecko DJ, Gao L, Shao Y, Guo B, et al. Bacterial delivery of siRNAs: a new approach to solid tumor therapy. Methods Mol Biol 2009; 487: 161-187.
12. Xiang S, Fruehauf J, Li C. Short hairpin RNA-expressing bacteria elicit RNA interference in mammals. Nat Biotechnol 2006; 24: 696.
13. Aouadi M, Tesz GJ, Nicoloro SM, Wang M, Chouinard M, Soto E, et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009; 458: 1180-1184.
14. Pascopella L, Raupach B, Ghori N, Monack D, Falkow S, Small PL. Host restriction phenotypes of Salmonella typhi and Salmonella gallinarum. Infect Immun 1995; 63: 4329-4335.
15. Wang X, Goode EL, Fredericksen ZS, Vierkant RA, Pankratz VS, Liu-Mares W, et al. Association of genetic variation in genes implicated in the b-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 2101-2108.
16. Saldanha G, Ghura V, Potter L, Fletcher A. Nuclear b-catenin in basal cell carcinoma correlates with increased proliferation'. Br J Dermatol 2004; 151: 157-164.
17. Takeuchi A. Electron microscope studies of experimental Salmonella infection. I. Penetration into the intestinal epithelium by Salmonella typhimurium. Am J Pathol 1967; 50: 109-136.
18. Carter PB, Collins FM. The route of enteric infection in normal mice. Exp Med 1974; 139: 1189-1203.
19. Bliska IB, Galan IE, Palkow S. Signal transduction in the mammalian cell during bacterial attachment and entry. Cell 1993; 73: 903-920.
20. Grillot-Courvalin C, Goussard S, Huetz F, Ojcius DM, Courvalin P. Functional gene transfer from intracellular bacteria to mammalian cells. Nat Biotechnol 1998; 16: 862-866.
21. Mathew E, Hardee GE, Bennett CF, Lee KD. Cytosolic delivery of antisense oligonucleo-tides by listeriolysin O-containing liposomes. Gene Ther 2003; 10: 1105-1115.
22. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987; 1: 1049-1052.
23. Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991; 338: 1055-1059.
24. Media Contact: Grossman C. Cequent Files its First IND with FDA: CEQ508, a tkRNAi Drug Candidate in Oncology. 12 November 2009.
25. Kochi SK, Killeen KP, Ryan US. Advances in the development of bacterial vector technology. Expert Rev Vaccines 2003; 2: 31-43.